-
InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal
•
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement with Lyvgen Biopharma, a Shanghai-based specialist in immuno-oncology therapeutics. According to the agreement, Lyvgen will transfer proprietary technology related to no more than three target antibodies to InventisBio, along with licensing patent rights and other…
-
Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC
•
Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized Phase II clinical study to assess the efficacy and safety of its LVGN7409 in combination with docetaxel or nivolumab for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC). The combination study is set to…
